Pathogenesis of Psoriatic Arthritis.
Journal
Critical reviews in immunology
ISSN: 1040-8401
Titre abrégé: Crit Rev Immunol
Pays: United States
ID NLM: 8914819
Informations de publication
Date de publication:
Historique:
entrez:
19
5
2020
pubmed:
1
1
2019
medline:
5
9
2020
Statut:
ppublish
Résumé
Psoriatic arthritis (PsA) is a chronic inflammatory arthropathy involving synovial and entheseal structures, associated with psoriasis or similar conditions. The etiopathogenetic mechanisms underlying PsA remain unclarified. The most accredited hypothesis involves a complex interaction among genetic, environmental, and immunological factors. Environmental agents, particularly trauma, mechanical stress, and smoke have been cited as possible factors in triggering the disease in genetically predisposed subjects. Like other forms of spondyloarthropathies, PsA shows several genetic associations with the major histocompatibility complex (MHC) class I alleles located on chromosome 6p21.3, particularly the human leukocyte antigen (HLA)-B27 in axial phenotypes. Recent studies have demonstrated that the most common epigenetic mechanisms that regulate gene expression in PsA are represented by DNA methylation, parent of origin effect or genomic imprinting, expression or activity of epigenetic modifying enzymes, and RNA interference (RNAi) by microRNAs (miRNAs). The mechanisms underlying PsA pathogenesis activate the innate and adaptive immune system and overexpression of TNF associated with amplification of the IL-23/IL-17 axis. In recent years, more PsA susceptibility genes and epigenetic mechanisms have been identified. Advances in the knowledge of innate and adaptive immune mechanisms underlying PsA have contributed to a better understanding of the heterogeneous clinical expression of the disease and, thus, to therapy strategies. The complexity of the pathogenetic aspects involving multiple cytokines, cell lines, and molecules needs to be further investigated to advance personalized therapeutic strategies and to improve outcomes of patients affected by PsA.
Identifiants
pubmed: 32422017
pii: 2a7315b36e01386e,41905f076fae9cd7
doi: 10.1615/CritRevImmunol.2020033243
doi:
Substances chimiques
HLA-B27 Antigen
0
Interleukin-17
0
Interleukin-23
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM